Mackay Martin
EVP & Global Head of R&D at ALEXION PHARMACEUTICALS INC
- Sold, on record
- $18.4M
- Dollars the filings state
- Form 4 sales
- 13
- Latest Mar 1, 2017
- Form 144 notices
- 0
- Proposed sales
- Companies
- 1
- Filed as an executive or holder
Companies
- ALEXION PHARMACEUTICALS INCEVP & Global Head of R&D
Sales by reason
Form 4 sales per month, last 12 months.
Timeline
- 1 Form 4 sale ALEXION PHARMACEUTICALS INCPlan not statedMay 14, 2015 2015
Sold 4,056 shares at $160.33 ($650k)
Mackay Martin, EVP & Global Head of R&D
Sold 11% of holdings ($5.9M position)32,893 shares left1x usual sizeFiling
- 2 Form 4 sale ALEXION PHARMACEUTICALS INCUnusualAug 3, 2015 +81 days
Sold 43,500 shares at $196.52 ($8.5M)
Mackay Martin, EVP & Global Head of R&D
Sold 56.9% of holdings ($15M position)32,893 shares left10.9x usual sizeFiling
- 3 Form 4 sale ALEXION PHARMACEUTICALS INCPlan not statedFeb 8, 2016 +189 days
Sold 3,971 shares at $139.84 ($555k)
Mackay Martin, EVP & Global Head of R&D
Sold 8.9% of holdings ($6.3M position)40,785 shares left1x usual sizeFiling
- 4 Form 4 sale ALEXION PHARMACEUTICALS INCPlan not statedFeb 29, 2016 +21 days
Sold 1,000 shares at $138.91 ($139k)
Mackay Martin, EVP & Global Head of R&D
Sold 2.1% of holdings ($6.6M position)46,785 shares left0.2x usual sizeFiling
- 5 Form 4 sale ALEXION PHARMACEUTICALS INCPlan not statedMay 16, 2016 +77 days
Sold 4,097 shares at $139.20 ($570k)
Mackay Martin, EVP & Global Head of R&D
Sold 8.8% of holdings ($6.5M position)42,688 shares left1x usual sizeFiling
- 6 Form 4 sale ALEXION PHARMACEUTICALS INCPlan not statedFeb 6, 2017 +266 days
Sold 2,728 shares at $125.70 ($343k)
Mackay Martin, EVP & Global Head of R&D
Sold 6.4% of holdings ($5.4M position)39,960 shares left0.7x usual sizeFiling
- 7 Form 4 sale ALEXION PHARMACEUTICALS INCPlan not statedFeb 9, 2017 +3 days
Sold 217 shares at $126.84 ($28k)
Mackay Martin, EVP & Global Head of R&D
Sold 0.5% of holdings ($5.1M position)39,743 shares left0.1x usual sizeFiling
- 8 Form 4 sale ALEXION PHARMACEUTICALS INCPlan not statedMar 1, 2017 +20 days
Sold 1,855 shares at $131.63 ($244k)
Mackay Martin, EVP & Global Head of R&D
Sold 3.5% of holdings ($6.9M position)50,688 shares left0.6x usual sizeFiling
Every transaction
Loading transactions…
Sales and notices (13)
| Source | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Mar 1, 2017 | Mar 1, 2017 | ALEXION PHARMACEUTICALS INC | EVP & Global Head of R&D | Form 4 sale | 1,855 | $244k | 3.5% | Plan not stated | SEC |
| Feb 9, 2017 | Feb 10, 2017 | ALEXION PHARMACEUTICALS INC | EVP & Global Head of R&D | Form 4 sale | 217 | $28k | 0.5% | Plan not stated | SEC |
| Feb 6, 2017 | Feb 8, 2017 | ALEXION PHARMACEUTICALS INC | EVP & Global Head of R&D | Form 4 sale | 2,728 | $343k | 6.4% | Plan not stated | SEC |
| May 16, 2016 | May 18, 2016 | ALEXION PHARMACEUTICALS INC | EVP & Global Head of R&D | Form 4 sale | 4,097 | $570k | 8.8% | Plan not stated | SEC |
| Feb 29, 2016 | Mar 1, 2016 | ALEXION PHARMACEUTICALS INC | EVP & Global Head of R&D | Form 4 sale | 1,000 | $139k | 2.1% | Plan not stated | SEC |
| Feb 8, 2016 | Feb 8, 2016 | ALEXION PHARMACEUTICALS INC | EVP & Global Head of R&D | Form 4 sale | 3,971 | $555k | 8.9% | Plan not stated | SEC |
| Aug 3, 2015 | Aug 5, 2015 | ALEXION PHARMACEUTICALS INC | EVP & Global Head of R&D | Form 4 sale | 43,500 | $8.5M | 56.9% | Unusual | SEC |
| May 14, 2015 | May 22, 2015 | ALEXION PHARMACEUTICALS INC | EVP & Global Head of R&D | Form 4 sale | 4,056 | $650k | 11.0% | Plan not stated | SEC |
| Mar 2, 2015 | Mar 3, 2015 | ALEXION PHARMACEUTICALS INC | EVP & Global Head of R&D | Form 4 sale | 370 | $67k | 1.0% | Plan not stated | SEC |
| Feb 10, 2015 | Feb 12, 2015 | ALEXION PHARMACEUTICALS INC | EVP & Global Head of R&D | Form 4 sale | 3,897 | $678k | 10.8% | Plan not stated | SEC |
| Nov 3, 2014 | Nov 4, 2014 | ALEXION PHARMACEUTICALS INC | EVP & Global Head of R&D | Form 4 sale | 9,375 | $1.8M | 27.7% | Unusual | SEC |
| Jun 12, 2014 | Jun 13, 2014 | ALEXION PHARMACEUTICALS INC | EVP & Global Head of R&D | Form 4 sale | 25,000 | $4.2M | 50.6% | Unusual | SEC |
| May 14, 2014 | May 15, 2014 | ALEXION PHARMACEUTICALS INC | EVP & Global Head of R&D | Form 4 sale | 3,574 | $575k | 12.8% | Plan not stated | SEC |